TNF blockers and hepatosplenic T-cell lymphoma linked

Article

FDA has received reports of hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease and ulcerative colitis being treated with tumor necrosis factor blockers, azathioprine, and mercaptopurine.

FDA has received reports of hepatosplenic T-cell lymphoma (HSTCL), a rare, aggressive cancer of white blood cells that usually is fatal, in adolescents and young adults with Crohn's disease and ulcerative colitis being treated with tumor necrosis factor (TNF) blockers (ie, infliximab, etanercept, adalimumab, certolizumab pegol, and golimumab), azathioprine, and mercaptopurine.

Several cases have occurred in patients being treated for rheumatoid arthritis and in 1 patient with psoriasis.

Although HSTCL was reported most often in those patients receiving a combination of medicines that suppress the immune system, including the TNF blockers, azathioprine, and/or mercaptopurine, there were some reports of HSTCL in patients who received azathioprine or mercaptopurine as monotherapies.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
Lori Handy, MD on importance of vaccine catch-up before the school year | Image credit: CHOP
Richard Wong, DO, explains challenges children with asthma face in school
Infectious Insights | Image Credit: Contemporary Pediatrics
John Browning, MD, provides practical skincare reminders ahead of summer season
Potential downstream benefits of RSV preventive measures, with Octavio Ramilo, MD
Discussing phase 3 data of Panzyga for PANS, with Michael Daines, MD
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
© 2025 MJH Life Sciences

All rights reserved.